Neuphoria Therapeutics Inc. (NEUP) — Financial statements
Income statement, balance sheet, and cash flow for Neuphoria Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 24 | 0.00 | 0.00↓100.0% | 0.28 | 0.00 | |
| Cost of Revenue | 1↑2.2% | 0.99↑47.8% | 0.67 | 0.00↓100.0% | 2 | |
| Gross Profit | 23↑2411.1% | -0.99↓47.8% | -0.67 | 0.00↑100.0% | -2 | |
| Operating Expenses | ||||||
| R&D Expenses | 14↓2.2% | 14↑6.5% | 13↓21.5% | 17↑194.4% | 6 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 11↓6.9% | 12↑40.0% | 8↓23.0% | 11↑96.2% | 6 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 25↓4.4% | 26↑19.5% | 22↓22.1% | 28↑146.2% | 11 | |
| Total Costs & Expenses | 26↓4.1% | 27↑20.4% | 22↓22.9% | 29↑123.1% | 13 | |
| Operating Results | ||||||
| Operating Income | -2↑93.5% | -27↓20.4% | -22↑22.2% | -29↓120.9% | -13 | |
| Depreciation & Amortization | 1↑2.2% | 0.99↑47.8% | 0.67↓42.6% | 1↓30.8% | 2 | |
| EBITDA | -0.27↑98.8% | -22↓3.7% | -22↑23.1% | -28↓322.8% | -7 | |
| EBIT | -1↑94.5% | -23↓5.0% | -22↑23.9% | -29↓250.9% | -8 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.17↓24.4% | 0.22↓31.9% | 0.32↑2862.9% | -0.01↑98.9% | -1 | |
| Interest Income | 0.17↓24.4% | 0.22↓31.9% | 0.32↑4660.0% | 0.01↑58.1% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.02↓98.3% | 1 | |
| Non-Operating Income | -0.45↑87.1% | -3↓8584.1% | -0.04↓106.7% | 0.60↑112.9% | -5 | |
| Other Income / Expenses | 0.45↓87.1% | 3↑8584.8% | 0.04↑106.2% | -0.64↓120.1% | 3 | |
| Income Before Tax | -1↑94.5% | -23↓5.0% | -22↑24.0% | -29↓199.8% | -10 | |
| Income Tax Expense | -0.72↓448.4% | -0.13↑77.0% | -0.57↑91.0% | -6↓468.7% | -1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -0.57↑97.6% | -23↓7.1% | -22↑5.6% | -23↓165.3% | -9 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -0.57↑97.6% | -23↓7.1% | -22↑5.6% | -23↓165.3% | -9 | |
| Bottom-Line Net Income | -0.57↑97.6% | -23↓7.1% | -22↑5.6% | -23↓165.3% | -9 | |
| EPS (Basic) | -0.23↓130.0% | -0.10↑41.2% | -0.17↓30.8% | -0.13↓30.0% | -0.10 | |
| EPS (Diluted) | -0.23↓130.0% | -0.10↑41.2% | -0.17↓30.8% | -0.13↓30.0% | -0.10 | |
| Weighted Average Shares | 2↓98.9% | 150↑22.4% | 122↑8.5% | 113↑73.5% | 65 | |
| Weighted Average Diluted Shares | 2↓98.9% | 150↑22.4% | 122↑8.5% | 113↑73.5% | 65 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.